
Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Panelists discuss the treatment options available for patients with early-stage versus advanced chronic kidney disease (CKD) and how these options should be tailored to individual patient conditions, as well as the mechanism of action of nonsteroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone and their comparison to other treatment modalities.






